Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - CSL Behring

Next Previous
Drug Profile

Immune globulin - CSL Behring

Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; human immunoglobulin G; IgNextGen 10%; IgPro10; IgPro20; Immune Globulin Subcutaneous [Human] 20% Liquid; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF; ScIG; Subcutaneous immunoglobulin; Tetagam P; Varicellon; Venimmun N; Vivaglobin

Latest Information Update: 07 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer Assistance Publique Hopitaux de Paris; CSL Behring; Georgetown University; Rigshospitalet; University of Oxford
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scleroderma; Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
  • Phase III Dermatomyositis; Encephalitis; Postural orthostatic tachycardia syndrome; Renal transplant rejection
  • Phase II Skin and soft tissue infections; Systemic scleroderma
  • No development reported Lung transplant rejection; Motor neuron disease; Pelvic inflammatory disorders; Spinal cord injuries; Systemic lupus erythematosus
  • Discontinued Diffuse scleroderma

Most Recent Events

  • 21 Feb 2025 CSL Behring terminates the phase III RECLAIIM trial in Dermatomyositis in US, France, Japan, Spain, Switzerland Germany, Russia and Ukraine (SC) since primary endpoint not attained (NCT04044690) (EUCT2018-003171-35)
  • 28 Aug 2024 Phase-III clinical trials in Postural orthostatic tachycardia syndrome in Canada, USA (SC) (NCT06524739)
  • 02 Aug 2024 CSL Behring plans to initiate a phase III trial for Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS) in the US (SC) (NCT06524739)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top